Portfolio
Early-Stage Life Science
Swedish life science technology company pioneering innovations in epigenetic research. Founded in 2020 as a spin-off from Karolinska Institutet, Epigenica has developed the EpiFinder™ platform—a first-in-class, high-throughput, multiplexed ChIP-seq technology that enables researchers to analyze multiple epigenetic markers across many samples simultaneously, with unprecedented speed, scalability, and affordability. Their patented technology overcomes key barriers in epigenomics by allowing for comprehensive, quantitative profiling of both DNA methylation and histone modifications, even from low input material.
More to come this autumn.
We look forward to presenting more investments later this year, all aimed at driving innovation and impact in the life science space.
PREVIOUS INVESTMENTS
Outcomes Models
PREVIOUS INVESTMENTS
The Outcomes Fund
Investment fund: Financing for a smarter welfare.
As a strategic seed and then later anchor investor in UFO, we continue to build on our previous experience with outcomes models by supporting this strategic initiative, enabling a platform for all Nordic outcomes financing. The fund has to date made the following investments in outcomes models:
￭ Härnösand Social Outcomes Contract on Elderly Care
￭ Gävle Social Outcomes Contract on Reading Ability
￭ Söderköping Social Outcomes Contract on Elderly Care
￭ Österåker Social Outcomes Contract on Primary Prevention